Last updated on February 2018

A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice


Brief description of study

This is a phase 3 randomized, multi-center, double-blind, placebo controlled, parallel group design study. This study is comprised of two phases: screening and treatment. The screening period is 24 hours, followed by the treatment phase of 15 3 days. During the treatment phase, subjects will be randomized to either test, reference of placebo treatments (3:3:1) in a double-blind manner in an outpatient setting. Once eligibility is confirmed, randomization will occur at visit 2 (baseline, Day 1) i.e. initiation of treatment phase. The treatment phase will be 15 3 days in duration wherein subject will receive treatment with investigational product (either test, reference or placebo) on Day 1 or baseline (visit 2). Efficacy will be evaluated at Day 15. Safety and tolerability will be evaluated based upon AEs and patient self-assessments and self-assessments collected during follow-up visits.

Clinical Study Identifier: NCT03337490

Contact Investigators or Research Sites near you

Start Over

Sumit Bajracharya

Site 105
Dinuba, CA United States
  Connect »

Sumit Bajracharya

Site 104
Miami, FL United States
  Connect »

Sumit Bajracharya

Site 101
Plantation, FL United States
  Connect »

Sumit Bajracharya

Site 102
West Palm Beach, FL United States
  Connect »

Sumit Bajracharya

Site 106
Nashville, TN United States
  Connect »

Sumit Bajracharya

Site 103
Richland, WA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.